RPID
NASDAQ · Life Sciences Tools & Services
Rapid Micro Biosystems Inc-A
$2.25
+0.03 (+1.35%)
Financial Highlights (FY 2026)
Revenue
28.39M
Net Income
-47,461,045
Gross Margin
-0.4%
Profit Margin
-167.2%
Rev Growth
+6.5%
D/E Ratio
0.00
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | -0.4% | -0.4% | 67.1% | 67.1% |
| Operating Margin | -178.0% | -160.2% | 15.2% | 14.6% |
| Profit Margin | -167.2% | -158.8% | 15.7% | 16.6% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 28.39M | 26.66M | 48.80M | 45.04M |
| Gross Profit | -110,731 | -103,982 | 32.74M | 30.22M |
| Operating Income | -50,527,862 | -42,703,611 | 7.43M | 6.55M |
| Net Income | -47,461,045 | -40,111,691 | 7.65M | 7.46M |
| Gross Margin | -0.4% | -0.4% | 67.1% | 67.1% |
| Operating Margin | -178.0% | -160.2% | 15.2% | 14.6% |
| Profit Margin | -167.2% | -158.8% | 15.7% | 16.6% |
| Rev Growth | +6.5% | +6.5% | +18.7% | +19.0% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 149.9K | 149.9K | 38.69M | 38.35M |
| Total Equity | 51.68M | 51.68M | 134.82M | 132.50M |
| D/E Ratio | 0.00 | 0.00 | 0.29 | 0.29 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -47,240,502 | -42,143,372 | 9.93M | 10.62M |
| Free Cash Flow | — | — | 5.64M | 3.34M |